Patents by Inventor Markus Britschgi

Markus Britschgi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating aging-associated cognitive impairment by reducing CCR3
    Patent number: 11912998
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: February 27, 2024
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
  • CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME
    Publication number: 20220213487
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Application
    Filed: December 14, 2021
    Publication date: July 7, 2022
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
  • Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)
    Patent number: 11236340
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: February 1, 2022
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
  • CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME
    Publication number: 20200399644
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Application
    Filed: April 7, 2020
    Publication date: December 24, 2020
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
  • Anti-alpha-synuclein antibodies and methods of use
    Patent number: 10647761
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: May 12, 2020
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
    Patent number: 10626399
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: April 21, 2020
    Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE
    Publication number: 20190292248
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Application
    Filed: March 20, 2019
    Publication date: September 26, 2019
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME
    Publication number: 20190185862
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Application
    Filed: January 6, 2017
    Publication date: June 20, 2019
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
  • Anti-alpha-synuclein antibodies and methods of use
    Patent number: 10316082
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: June 11, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME
    Publication number: 20190024091
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul A. Villeda
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE
    Publication number: 20180237510
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Application
    Filed: December 19, 2017
    Publication date: August 23, 2018
    Inventors: Klaus KALUZA, Olaf MUNDIGL, Thomas KREMER, Markus BRITSCHGI, Sylwia HUBER
  • Anti-alpha-synuclein antibodies and methods of use
    Patent number: 9890209
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: February 13, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE
    Publication number: 20170327566
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Application
    Filed: April 26, 2017
    Publication date: November 16, 2017
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • Anti-alpha-synuclein antibodies and methods of use
    Patent number: 9670274
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: June 6, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND METHODS OF USE
    Publication number: 20170114123
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Application
    Filed: October 3, 2016
    Publication date: April 27, 2017
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • Anti-alpha-synuclein antibodies and methods of use
    Patent number: 9493553
    Abstract: Provided herein are anti-human alpha-synuclein antibodies, including, for example, antibodies that bind to human alpha-synuclein which has a free N-terminal methionine residue, and methods of using the same.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: November 15, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME
    Publication number: 20160208011
    Abstract: Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 21, 2016
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul Abraham Villeda
  • ANTI-alpha-SYNUCLEIN ANTIBODIES AND METHODS OF USE
    Publication number: 20150140003
    Abstract: The invention provides anti-human alpha-synuclein antibodies and methods of using the same.
    Type: Application
    Filed: November 20, 2014
    Publication date: May 21, 2015
    Inventors: Klaus Kaluza, Olaf Mundigl, Thomas Kremer, Markus Britschgi, Sylwia Huber
  • BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS
    Publication number: 20140255424
    Abstract: Provided are methods of diagnosis, prognosis, and monitoring of aging using biomarkers that have been discovered to be linked to biological aging process. Methods for increasing neural cell regeneration and cognitive function are also provided. The methods are, at least in part, based on a discovery that altered expression patterns of certain biological markers are associated with biological aging processes. These markers comprise at least Eotaxin/CCL11, ?2-microglobulin, MCP-1 and Haptoglobulin, increased expression of which has been shown to be associated with increase in biological aging process.
    Type: Application
    Filed: May 19, 2014
    Publication date: September 11, 2014
    Applicants: The Board of Trustees of the Leland Stanford Junior University, Department of Veterans Affairs
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul Abraham Villeda
  • BIOMARKERS OF AGING FOR DETECTION AND TREATMENT OF DISORDERS
    Publication number: 20130040844
    Abstract: Provided are methods of diagnosis, prognosis, and monitoring of aging using biomarkers that have been discovered to be linked to biological aging process. Methods for increasing neural cell regeneration and cognitive function are also provided. The methods are, at least in part, based on a discovery that altered expression patterns of certain biological markers are associated with biological aging processes. These markers comprise at least Eotaxin/CCL11, 2-microglobulin, MCP-1 and Hap-toglobulin, increased expression of which has been shown to be associated with increase in biological aging process.
    Type: Application
    Filed: January 28, 2011
    Publication date: February 14, 2013
    Applicants: The Board of Trustees of the Leland Stanford Junior University, DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Anton Wyss-Coray, Thomas A. Rando, Markus Britschgi, Kaspar Rufibach, Saul Abraham Villeda